WO2001062927A3 - Polypeptides and corresponding polynucleotides for diagnostics and therapeutics - Google Patents

Polypeptides and corresponding polynucleotides for diagnostics and therapeutics Download PDF

Info

Publication number
WO2001062927A3
WO2001062927A3 PCT/US2001/006059 US0106059W WO0162927A3 WO 2001062927 A3 WO2001062927 A3 WO 2001062927A3 US 0106059 W US0106059 W US 0106059W WO 0162927 A3 WO0162927 A3 WO 0162927A3
Authority
WO
WIPO (PCT)
Prior art keywords
dithp
therapeutics
diagnostics
polypeptides
provides
Prior art date
Application number
PCT/US2001/006059
Other languages
French (fr)
Other versions
WO2001062927A2 (en
Inventor
Scott R. Panzer
Peter A. Spiro
Steven C. Banville
Purvi Shah
Michael S. Chalup
Simon C. Chang
Alice Chen
Steven A. D'sa
Stefan Amshey
Christopher R. Dahl
Tam C. Dam
Susan E. Daniels
Gerard E. Dufour
Vincent Flores
Willy T. Fong
Lila B. Greenawalt
Jennifer L. Hillman
Anissa L. Jones
Tommy F. Liu
Ann M. Roseberry
Bruce H. Rosen
Frank D. Russo
Theresa K. Stockdreher
Abel Daffo
Rachel J. Wright
Pierre E. Yap
Jimmy Y. Yu
Diana L. Bradley
Shawn R. Bratcher
Wensheng Chen
Howard J. Cohen
David M. Hodgson
Stephen E. Lincoln
Stuart Jackson
Original Assignee
Incyte Genomics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics, Inc. filed Critical Incyte Genomics, Inc.
Priority to CA002401868A priority Critical patent/CA2401868A1/en
Priority to EP01913041A priority patent/EP1265998A2/en
Priority to US10/220,120 priority patent/US20040048253A1/en
Priority to AU4175401A priority patent/AU4175401A/en
Publication of WO2001062927A2 publication Critical patent/WO2001062927A2/en
Publication of WO2001062927A3 publication Critical patent/WO2001062927A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides purified human polynucleotides for diagnostics and therapeutics (dithp). Also encompassed are the polypeptides (DITHP) encoded by dithp. The invention also provides for the use of dithp, or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing dithp for the expression of DITHP. The invention additionally provides for the use of isolated and purified DITHP to induce antibodies and to screen libraries of compounds and the use of anti-DITHP antibodies in diagnostic assays. Also provided are microarrays containing dithp and methods of use.
PCT/US2001/006059 2000-02-24 2001-02-21 Polypeptides and corresponding polynucleotides for diagnostics and therapeutics WO2001062927A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002401868A CA2401868A1 (en) 2000-02-24 2001-02-21 Molecules for diagnostics and therapeutics
EP01913041A EP1265998A2 (en) 2000-02-24 2001-02-21 Polypeptides and corresponding polynucleotides for diagnostics and therapeutics
US10/220,120 US20040048253A1 (en) 2001-02-21 2001-02-21 Molecules for diagnostics and therapeutics
AU4175401A AU4175401A (en) 2000-02-24 2001-02-26 Molecules for diagnostics and therapeutics

Applications Claiming Priority (65)

Application Number Priority Date Filing Date Title
US18477300P 2000-02-24 2000-02-24
US18521300P 2000-02-24 2000-02-24
US18469700P 2000-02-24 2000-02-24
US18476900P 2000-02-24 2000-02-24
US18477000P 2000-02-24 2000-02-24
US18476800P 2000-02-24 2000-02-24
US18483700P 2000-02-24 2000-02-24
US18477400P 2000-02-24 2000-02-24
US18481300P 2000-02-24 2000-02-24
US18477200P 2000-02-24 2000-02-24
US18469800P 2000-02-24 2000-02-24
US18477600P 2000-02-24 2000-02-24
US18477100P 2000-02-24 2000-02-24
US18521600P 2000-02-24 2000-02-24
US18484100P 2000-02-24 2000-02-24
US18477700P 2000-02-24 2000-02-24
US18479700P 2000-02-24 2000-02-24
US18469300P 2000-02-24 2000-02-24
US60/185,216 2000-02-24
US60/185,213 2000-02-24
US60/184,777 2000-02-24
US60/184,813 2000-02-24
US60/184,774 2000-02-24
US60/184,769 2000-02-24
US60/184,841 2000-02-24
US60/184,693 2000-02-24
US60/184,771 2000-02-24
US60/184,776 2000-02-24
US60/184,697 2000-02-24
US60/184,772 2000-02-24
US60/184,768 2000-02-24
US60/184,837 2000-02-24
US60/184,797 2000-02-24
US60/184,770 2000-02-24
US60/184,773 2000-02-24
US60/184,698 2000-02-24
US20378500P 2000-05-12 2000-05-12
US60/203,785 2000-05-12
US20422600P 2000-05-15 2000-05-15
US60/204,226 2000-05-15
US20452500P 2000-05-16 2000-05-16
US20490800P 2000-05-16 2000-05-16
US20523200P 2000-05-16 2000-05-16
US20482100P 2000-05-16 2000-05-16
US60/204,821 2000-05-16
US60/204,908 2000-05-16
US60/204,525 2000-05-16
US60/205,232 2000-05-16
US20532100P 2000-05-17 2000-05-17
US20522100P 2000-05-17 2000-05-17
US20528700P 2000-05-17 2000-05-17
US20486300P 2000-05-17 2000-05-17
US20532400P 2000-05-17 2000-05-17
US20528600P 2000-05-17 2000-05-17
US20481500P 2000-05-17 2000-05-17
US20528500P 2000-05-17 2000-05-17
US20532300P 2000-05-17 2000-05-17
US60/205,323 2000-05-17
US60/205,221 2000-05-17
US60/205,285 2000-05-17
US60/205,324 2000-05-17
US60/205,287 2000-05-17
US60/204,815 2000-05-17
US60/204,863 2000-05-17
US60/205,286 2000-05-17

Publications (2)

Publication Number Publication Date
WO2001062927A2 WO2001062927A2 (en) 2001-08-30
WO2001062927A3 true WO2001062927A3 (en) 2002-04-25

Family

ID=27586913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006059 WO2001062927A2 (en) 2000-02-24 2001-02-21 Polypeptides and corresponding polynucleotides for diagnostics and therapeutics

Country Status (1)

Country Link
WO (1) WO2001062927A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1278863A2 (en) * 2000-05-12 2003-01-29 MERCK PATENT GmbH Human serine-threonine kinase-4
EP1292685A2 (en) * 2000-06-23 2003-03-19 Incyte Genomics, Inc. Human lyases
AU2002250143A1 (en) * 2001-03-16 2002-10-03 Eli Lilly And Company Lp mammalian proteins; related reagents
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20070037204A1 (en) 2003-08-08 2007-02-15 Hiroyuki ABURANTAI Gene overexpressed in cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045712A2 (en) * 1997-04-08 1998-10-15 Human Genome Sciences, Inc. 20 human secreted proteins
WO1998048274A1 (en) * 1997-04-22 1998-10-29 Smithkline Beecham Corporation Homogeneous fluorescence assay for measuring the effect of compounds on gene expression
WO1999025825A2 (en) * 1997-11-13 1999-05-27 Genset EXTENDED cDNAs FOR SECRETED PROTEINS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045712A2 (en) * 1997-04-08 1998-10-15 Human Genome Sciences, Inc. 20 human secreted proteins
WO1998048274A1 (en) * 1997-04-22 1998-10-29 Smithkline Beecham Corporation Homogeneous fluorescence assay for measuring the effect of compounds on gene expression
WO1999025825A2 (en) * 1997-11-13 1999-05-27 Genset EXTENDED cDNAs FOR SECRETED PROTEINS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE SWALL [online] 1 October 1996 (1996-10-01), TAKAHASHI M. ET AL.: "ALCOHOL DEHYDROGENASE [NADP+] (EC 1.1.1.2) (ALDEHYDE REDUCTASE)", XP002174107, retrieved from EBI Database accession no. P51635 *
TAKAHASHI MOTOKO ET AL: "Identity of a major 3-deoxyglucosone-reducing enzyme with aldehyde reductase in rat liver established by amino acid sequencing and cDNA expression.", GENE (AMSTERDAM), vol. 127, no. 2, 1993, pages 249 - 253, XP002174106, ISSN: 0378-1119 *

Also Published As

Publication number Publication date
WO2001062927A2 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
WO2002097031A3 (en) Molecules for diagnostics and therapeutics
WO2004023973A3 (en) Molecules for diagnostics and therapeutics
WO2000073509A3 (en) Molecules for diagnostics and therapeutics
PL399351A1 (en) Antibody molecule, a compound containing it, DNA sequence, cloning and expression vector, host cell, method for preparing an antibody molecule, therapeutic or diagnostic composition, the use of a molecule or a compound
WO2001038486A3 (en) Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies
WO2002083876A3 (en) Secretory molecules
WO2002046228A3 (en) Receptor for b. anthracis toxin
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
WO2002012338A3 (en) Screening method
WO2003062376A3 (en) Molecules for diagnostics and therapeutics
WO2002040715A8 (en) Molecules for disease detection and treatment
WO2002020756A3 (en) Secretory molecules
WO2001066690A3 (en) Novel compounds
WO2001062927A3 (en) Polypeptides and corresponding polynucleotides for diagnostics and therapeutics
WO2002020754A3 (en) Molecules for diagnostics and therapeutics
WO2001062918A3 (en) Secretory polypeptides and corresponding polynucleotides
WO2003062385A3 (en) Secretory molecules
WO2001062922A3 (en) Polypeptides and corresponding molecules for disease detection and treatment
WO2001072961A3 (en) Novel compounds
WO2002018576A3 (en) Compositions and methods relating to lung specific genes
WO2002055738A3 (en) Molecules for disease detection and treatment
WO2001021836A3 (en) Molecules for diagnostics and therapeutics
WO2002079473A3 (en) Molecules for diagnostics and therapeutics
WO2001061055A3 (en) Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes
WO2000075298A8 (en) Molecules for disease detection and treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

WWE Wipo information: entry into national phase

Ref document number: 2401868

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001913041

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2001913041

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10220120

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001913041

Country of ref document: EP